Traws Pharma (TRAW) Q4 2024 & Study Update earnings summary

Executive summary

• Presented two antiviral candidates: tivoxavir marboxil for bird flu and ratutrelvir for COVID, both positioned as best-in-class with broad resistance profiles and strong preclinical and early clinical data.

• Tivoxavir marboxil demonstrated potent efficacy in animal models (mice, ferrets, non-human primates) and favorable pharmacokinetics, supporting single-dose therapy for up to three weeks.

• Ratutrelvir showed superior potency to current COVID antivirals, a unique resistance profile, and does not require ritonavir, addressing key limitations of Paxlovid.

• Refocused on respiratory viral diseases, prioritizing bird flu with lead candidate tivoxavir marboxil; positive preclinical and Phase 1 data support accelerated FDA pathway discussions.

• CEO transition announced: Werner Cautreels retiring, Iain D. Dukes appointed Interim CEO.

Financial highlights

• Cash and cash equivalents plus short-term investments totaled $21.3 million as of December 31, 2024, up from $20.8 million in 2023.

• Net loss for 2024 was $166.5 million, primarily due to $117.5 million acquired in-process R&D and $24.4 million warrant expense; net loss per share was $35.21.

• R&D expenses increased to $12.8 million, mainly for clinical/preclinical trials and personnel.

• G&A expenses rose to $12.3 million, driven by consulting fees for strategic alternatives.

• 5,073,790 shares outstanding as of March 26, 2025, reflecting 3.9 million new shares from December financing.

Outlook and guidance

• Cash runway expected to support operations into Q1 2026.

• Tivoxavir marboxil: FDA feedback on Animal Rule pathway expected in Q2 2025; ongoing formulation and CMC scale-up.

• Ratutrelvir: Pre-IND meeting with FDA planned to define milestones and endpoints for Long COVID development in Q2 2025.

• Market potential for bird flu estimated at 300,000–600,000 stockpiled doses; COVID market outlook aligns with current Paxlovid sales, exceeding $5 billion.